SCHEMBL420469

SCHEMBL420469

O=C1CCCC(OCc2ccccc2)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PSEN1 P49768 2/20 0.50
PSEN2 P49810 2/20 0.50
APH1B Q8WW43 2/20 0.50
NCSTN Q92542 2/20 0.50
APH1A Q96BI3 2/20 0.50
PSENEN Q9NZ42 2/20 0.50
CYP3A4 P08684 1/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 1/20 0.48
OPRM1 P35372 2/20 0.46
OPRL1 P41146 2/20 0.46
DPP4 P27487 1/20 0.46
SIGMAR1 Q99720 2/20 0.44
TMEM97 Q5BJF2 1/20 0.43
CARM1 Q86X55 1/20 0.43
PRMT6 Q96LA8 1/20 0.43
PRMT8 Q9NR22 1/20 0.43
HRH3 Q9Y5N1 1/20 0.43
CTSL P07711 2/20 0.43
CTSB P07858 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL416422 0.93 OPRM1 (0.50) PSEN1PSEN2APH1BNCSTNAPH1A
Ethylene SCHEMBL7936439 0.90 OPRM1 (0.48) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL7753890 0.84 ESR2 (0.47) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL1288390 0.83 CYP3A4 (0.47) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL7985833 0.83 CYP3A4 (0.47) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL355570 0.82 OPRM1 (0.56) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL3660170 0.82 OPRM1 (0.56) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL9131464 0.81 CTSL (0.56) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL61112 0.81 CTSL (0.56) PSEN1PSEN2APH1BNCSTNAPH1A
Ammonia Solution, Strong SCHEMBL5339394 0.81 OPRM1 (0.54) PSEN1PSEN2APH1BNCSTNAPH1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120022045-A1 BRIDGED COMPOUNDS AS HIV INTEGRASE INHIBITORS VENKATRAMAN SHANKAR (US) 2012-01-26 US disclosed
EP-2391212-A1 BRIDGED COMPOUNDS AS HIV INTEGRASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2011-12-07 EP disclosed
WO-2010088167-A1 BRIDGED COMPOUNDS AS HIV INTEGRASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2010-08-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022045-A1 BRIDGED COMPOUNDS AS HIV INTEGRASE INHIBITORS CCND3, CDK3, CDK2 PSEN1 2534/4885PSEN2 2724/4885APH1B 1785/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.